MiMedx Clarifies Sanara Merger Terms and Secures $300M Financing

Key Facts

In a move that enhances transparency regarding healthcare sector consolidations, MiMedx Group has clarified the final financial terms for its acquisition of Sanara MedTech Inc. According to reports, the deal structure dictates that each share of Sanara common stock will be converted into $33.00 in cash plus 0.4735 shares of MiMedx common stock. To support the transaction, MiMedx has secured a $300 million first-lien senior secured term loan commitment to finance the merger and refinance existing debt.

The latest disclosures also specified merger termination fees, setting a $9.66 million penalty for Sanara and a $22.54 million fee for MiMedx under specific failure-to-close scenarios. The transaction remains subject to customary closing conditions, including approval from Sanara stockholders—where holders representing approximately 38.9% of voting power are already under a voting agreement—as well as antitrust clearance and the formal listing of new shares on the Nasdaq.

While current price levels for the instruments were unavailable at the time of this report, investors are looking toward the fulfillment of regulatory requirements to finalize Sanara's status as a wholly owned subsidiary. Regarding upcoming catalysts, market participants may monitor U.S. Initial Jobless Claims and scheduled Fed speeches on August 6, 2026, for broader signals on financing conditions and sector liquidity.